Revolution in cancer therapy: Vidac Pharma attacks the cancer throne of the big players! Why the smaller competitor could steal the show from giants like Bayer and BioNTech!

Vidac Pharma: Groundbreaking innovations

This news gives cause for hope, as Vidac Pharma has taken an important, major step forward in the development of its cancer therapies. The company announced that the first patient in a Phase 2b clinical trial has been successfully treated with the drug candidate VDA-1102. It is important to note that the focus here is on actinic keratosis (AK), a common precancerous skin condition. What makes Vidac's technology special is its ability to repair the disturbed metabolism of cancer cells. By specifically targeting the enzyme hexokinase-2, programmed cell death is reactivated in malignant cells without damaging the surrounding healthy tissue.

However, the momentum at Vidac Pharma is not limited to the laboratory. Dr. Max Herzberg, the visionary behind the company, underscores his deep confidence in Vidac's future with massive personal investments. To further accelerate growth and remain attractive to top talent, the board has launched a new employee participation program. Up to 10% of the share capital may in future be distributed in the form of options to the people who work every day on the innovations of tomorrow. The Israeli subsidiary is now allowed to carry out capital increases of up to EUR 5 million in order to bring new partners on board. With the appointment of Dr. Oren Menahem Becker to the Board of Directors, the company is also strengthening its scientific expertise.

In terms of chart analysis, the share price is consolidating its rapid rise after reaching a high of just under EUR 1 in a kind of pennant formation. There is repeated light selling pressure between EUR 0.75 and EUR 0.80, with stronger support at the EUR 0.70 level. If the share price manages to break through the EUR 0.80 mark, the derived price target is EUR 1.10–1.20. This seems entirely achievable given the potentially positive news flow ahead.

Bayer: Hope for a golden future

While Vidac Pharma is impressing with a breath of fresh air, the long-established Leverkusen-based Bayer Group has navigated much stormier waters in recent months and years. Although operating earnings are likely to have been significantly better last year and consolidated sales are an impressive EUR 46 billion, the risks from the glyphosate litigation weighed heavily on the stock for years. Just over a year ago, the share price was below EUR 20. It was only in the last 12 months that it began to rise to over EUR 40. Now, a completely different game is being played. The focus is on what the individual divisions could be worth. The market valuation of around EUR 40 billion shows that the group may currently be trading at below its true value on the stock market, considering the strength and potential value of the individual divisions.

It becomes particularly exciting when looking at Bayer's pharmaceuticals division in isolation. Experts estimate that this division alone could be worth around EUR 72 billion based on a conservative valuation, which is significantly more than the current total value of the group. There are five potential blockbuster drugs in the pipeline that could secure sales well into the next decade. It is precisely this discrepancy between the current stock market price and the true value of the individual parts that is fueling the imagination of financial investors. There is speculation that splitting the group into the Crop Science, Pharmaceuticals, and Consumer Health divisions could unlock enormous value. CEO Bill Anderson is sticking to the integrated structure for the time being, but the pressure is growing. Analysts at JPMorgan and Barclays already see the fair value of the share at EUR 50, while an actual takeover by financial investors could even push the price up to EUR 65. Highly speculative!

BioNTech: The power of mRNA technology after the pandemic

The transition from a classic giant like Bayer to a modern pioneer like BioNTech shows how diverse the industry is. BioNTech has changed the world with its COVID vaccine and now sits on a nice cash pile, which in turn is helping to usher in the next era of medicine. The Mainz-based company has long been in the process of transferring its technological platform to other areas such as oncology and infectious diseases. Investor expectations are high as the market now awaits the results of the broad cancer pipeline following the decline in pandemic revenues.

Similar to Vidac Pharma, BioNTech is also focusing on a novel approach. However, BioNTech's approach is no longer so novel, as mRNA technology has already been established for a few years now. In addition, the Mainz-based company has the advantage of having well-filled coffers and a global presence and reputation. Now BioNTech just has to show that the success of the vaccine was not a one-off, but the beginning of a diverse range of treatment options. BioNTech has an extensive pipeline of cancer drugs and aims to launch its first oncology treatment by 2026. Up to 10 additional drugs could potentially reach oncological indications in the following four years. If this happens, the share price is likely to be significantly higher than it is now.

In summary, the pharmaceutical and biotech sector is currently in an extremely exciting phase. Bayer offers an interesting story, with investors hoping for a legal resolution to the Monsanto debacle and, at the same time, a possible increase in value through corporate restructuring. BioNTech, on the other hand, represents established future technology that now has to prove itself in new therapeutic fields. However, the potential highlight remains Vidac Pharma. With the successful dosing of the first patient in the Phase 2b study and the massive backing of Dr. Max Herzberg, the company is showing great momentum. With a share price of around EUR 0.75, Vidac Pharma offers an opportunity for investors who want to be part of a potential medical revolution from the very beginning.